Cytokinetics Reports Third Quarter Financial Results Exceeding Analyst Expectations
Cytokinetics, Inc. (CYTK) reported third-quarter financial results that surpassed market estimates for both earnings and revenue. The company posted a GAAP earnings per share (EPS) of -$1.37, which outperformed expectations by $0.09, and recorded total revenue of $47.6 million, beating consensus estimates by $5.26 million. The results come amid significant clinical activity for the company, including the release of full data from late-stage trials for its lead drug candidate targeting non-obstructive hypertrophic cardiomyopathy (HCM). The earnings beat highlights a stronger-than-anticipated financial performance as the company continues to advance its product pipeline and participate in major healthcare industry conferences.
Tickers: $CYTK
Topics: biotechnology earnings beat GAAP EPS revenue beat
Read the full article at Seeking Alpha
Part of the story Crescent Energy Company Reports Third Quarter Financial Results (3 articles)